Kidney Cancer Trial, Recruiting NCT06769893 Sponsor: Xijing Hospital Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT06769893
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You (or your legal guardian/caregiver) must be willing and able to sign a consent form agreeing to take part.
  • You must be between 18 and 75 years old.
  • You must have a suspected kidney cancer diagnosis based on standard imaging scans, and be scheduled to have a special type of scan called a 68Ga-PSMA PET/CT.
  • Your standard imaging scans or the 68Ga-PSMA PET/CT scan must show possible signs that cancer may have spread to lymph nodes or other parts of the body.
  • You must be willing and able to follow all the steps of the study plan.

Who may not be able to join:

  • You have already received any cancer treatment before having the PET/CT scan.
  • You have a serious condition affecting the nervous system, heart, stomach or gut, liver, kidneys, blood, breathing, or immune system.
  • You have a reason why you cannot have a PET/CT scan — for example, you cannot tolerate repeated injections into a vein, you may be allergic to the scan drug or its ingredients, or you experience severe anxiety in enclosed spaces (claustrophobia).
  • You have been diagnosed with another type of cancer within the past year.
  • You have had a major operation within the past 3 months.
  • You have received an experimental drug or device treatment within the past month, or are currently taking part in another clinical trial involving a treatment.
  • You are pregnant or currently breastfeeding.
  • You are likely to be unable to attend follow-up appointments.
  • There is any other reason the research team believes could affect the study or make it unsafe or unsuitable for you to take part (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0086+15991459177

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Xijing Hospital
Registry
ClinicalTrials.gov
Start date
12 June 2024
Est. completion
1 April 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Maximum Standardized uptake value (SUVmax); Mean Standardized Uptake Value(SUVmean) of liver; Tumor to Background Ratio(TBR); The correlation between CD70 expression and [18F]RCCB6 uptake value

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov